L Citrome

Summary

Affiliation: Nathan Kline Institute
Country: USA

Publications

  1. ncbi Introduction: weighing the evidence: weight management insights for treating major mental illness
    Leslie Citrome
    Department of Psychiatry, New York University School of Medicine, New York, USA
    J Clin Psychiatry 68:4. 2007
  2. pmc Patient perspectives in the development and use of long-acting antipsychotics in schizophrenia: focus on olanzapine long-acting injection
    Leslie Citrome
    New York University School of Medicine, Department of Psychiatry, and the Nathan S Kline Institute for Psychiatric Research, Orangeburg, NY, USA
    Patient Prefer Adherence 3:345-55. 2009
  3. ncbi Dosing of quetiapine in schizophrenia: how clinical practice differs from registration studies
    Leslie Citrome
    Nathan S Kline Institute for Psychiatric Research, 140 Old Orangeburg Road, Orangeburg, NY 10962, USA
    J Clin Psychiatry 66:1512-6. 2005
  4. doi Interpreting and applying the EUFEST results using number needed to treat: antipsychotic effectiveness in first-episode schizophrenia
    L Citrome
    New York University School of Medicine, Department of Psychiatry, Nathan S Kline Institute for Psychiatric Research, Orangeburg, NY, USA
    Int J Clin Pract 62:837-40. 2008
  5. ncbi Did CATIE influence antipsychotic use?
    Leslie Citrome
    Nathan S Kline Institute for Psychiatric Research, Orangeburg, NY 10962, USA
    Psychiatr Serv 59:476. 2008
  6. doi Current guidelines and their recommendations for prolactin monitoring in psychosis
    Leslie Citrome
    New York University School of Medicine, Department of Psychiatry, and the Nathan S Kline Institute for Psychiatric Research, 140 Old Orangeburg Road, Orangeburg, NY 10962, USA
    J Psychopharmacol 22:90-7. 2008
  7. doi Compelling or irrelevant? Using number needed to treat can help decide
    L Citrome
    Department of Psychiatry, New York University School of Medicine, The Nathan S Kline Institute for Psychiatric Research, Orangeburg, NY 10962, USA
    Acta Psychiatr Scand 117:412-9. 2008
  8. ncbi Schizophrenia, Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) and number needed to treat: how can CATIE inform clinicians?
    L Citrome
    Department of Psychiatry, New York University School of Medicine, New York, NY, USA
    Int J Clin Pract 60:933-40. 2006
  9. doi Antipsychotics for the treatment of schizophrenia: likelihood to be helped or harmed, understanding proximal and distal benefits and risks
    Leslie Citrome
    New York University School of Medicine, Department of Psychiatry, and the Nathan S Kline Institute for Psychiatric Research, 140 Old Orangeburg Road, Orangeburg, NY 10962, USA
    Expert Rev Neurother 8:1079-91. 2008
  10. doi Schizophrenia, obesity, and antipsychotic medications: what can we do?
    Leslie Citrome
    New York University School of Medicine, Department of Psychiatry, and the Nathan S Kline Institute for Psychiatric Research, Orangeburg, NY 10962, USA
    Postgrad Med 120:18-33. 2008

Detail Information

Publications95

  1. ncbi Introduction: weighing the evidence: weight management insights for treating major mental illness
    Leslie Citrome
    Department of Psychiatry, New York University School of Medicine, New York, USA
    J Clin Psychiatry 68:4. 2007
  2. pmc Patient perspectives in the development and use of long-acting antipsychotics in schizophrenia: focus on olanzapine long-acting injection
    Leslie Citrome
    New York University School of Medicine, Department of Psychiatry, and the Nathan S Kline Institute for Psychiatric Research, Orangeburg, NY, USA
    Patient Prefer Adherence 3:345-55. 2009
    ..07% of injections, requiring a risk management plan that includes observing the patient for 3 hours post injection...
  3. ncbi Dosing of quetiapine in schizophrenia: how clinical practice differs from registration studies
    Leslie Citrome
    Nathan S Kline Institute for Psychiatric Research, 140 Old Orangeburg Road, Orangeburg, NY 10962, USA
    J Clin Psychiatry 66:1512-6. 2005
    ..The purpose of this article is to review the past and present dosing patterns of quetiapine for the treatment of schizophrenia...
  4. doi Interpreting and applying the EUFEST results using number needed to treat: antipsychotic effectiveness in first-episode schizophrenia
    L Citrome
    New York University School of Medicine, Department of Psychiatry, Nathan S Kline Institute for Psychiatric Research, Orangeburg, NY, USA
    Int J Clin Pract 62:837-40. 2008
  5. ncbi Did CATIE influence antipsychotic use?
    Leslie Citrome
    Nathan S Kline Institute for Psychiatric Research, Orangeburg, NY 10962, USA
    Psychiatr Serv 59:476. 2008
  6. doi Current guidelines and their recommendations for prolactin monitoring in psychosis
    Leslie Citrome
    New York University School of Medicine, Department of Psychiatry, and the Nathan S Kline Institute for Psychiatric Research, 140 Old Orangeburg Road, Orangeburg, NY 10962, USA
    J Psychopharmacol 22:90-7. 2008
    ..These decisions would be within the context of considering other adverse events as well as the overall effectiveness of the antipsychotic medication being used...
  7. doi Compelling or irrelevant? Using number needed to treat can help decide
    L Citrome
    Department of Psychiatry, New York University School of Medicine, The Nathan S Kline Institute for Psychiatric Research, Orangeburg, NY 10962, USA
    Acta Psychiatr Scand 117:412-9. 2008
    ....
  8. ncbi Schizophrenia, Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) and number needed to treat: how can CATIE inform clinicians?
    L Citrome
    Department of Psychiatry, New York University School of Medicine, New York, NY, USA
    Int J Clin Pract 60:933-40. 2006
    ..NNT and NNH can help place the wide array of CATIE results into clinical context, and permits quantification of the differences observed between the antipsychotics that were tested...
  9. doi Antipsychotics for the treatment of schizophrenia: likelihood to be helped or harmed, understanding proximal and distal benefits and risks
    Leslie Citrome
    New York University School of Medicine, Department of Psychiatry, and the Nathan S Kline Institute for Psychiatric Research, 140 Old Orangeburg Road, Orangeburg, NY 10962, USA
    Expert Rev Neurother 8:1079-91. 2008
    ..The examples provided are extensions to the initially published NNT and NNH analyses conducted by the first author...
  10. doi Schizophrenia, obesity, and antipsychotic medications: what can we do?
    Leslie Citrome
    New York University School of Medicine, Department of Psychiatry, and the Nathan S Kline Institute for Psychiatric Research, Orangeburg, NY 10962, USA
    Postgrad Med 120:18-33. 2008
    ..At the very least, a "small-steps approach" to managing weight should be offered to all patients who are overweight or obese...
  11. doi Public-academic partnerships: integrating state psychiatric hospital treatment and clinical research
    Leslie Citrome
    Nathan S Kline Institute forPsychiatric Research, 140 Old Orangeburg Rd, Orangeburg, NY 10962, USA
    Psychiatr Serv 59:958-60. 2008
    ..Kline Institute for Psychiatric Research, colocated on the same campus as Rockland Psychiatric Center, each of which is an independent facility operated by the New York State Office of Mental Health...
  12. ncbi Comparison of intramuscular ziprasidone, olanzapine, or aripiprazole for agitation: a quantitative review of efficacy and safety
    Leslie Citrome
    Department of Psychiatry, New York University School of Medicine, and the Nathan S Kline Institute for Psychiatric Research, Orangeburg, NY 10962, USA
    J Clin Psychiatry 68:1876-85. 2007
    ..To compare the efficacy and safety of the intramuscular formulations of ziprasidone, olanzapine, and aripiprazole in treating agitation...
  13. ncbi Datapoints: The ups and downs of dosing second-generation antipsychotics
    Leslie Citrome
    Department of Psychiatry, New York University School of Medicine, New York City, USA
    Psychiatr Serv 58:11. 2007
  14. ncbi The effectiveness criterion: balancing efficacy against the risks of weight gain
    Leslie Citrome
    Department of Psychiatry, New York University School of Medicine, New York, USA
    J Clin Psychiatry 68:12-7. 2007
    ..Predictors of weight gain for olanzapine are reviewed for schizophrenia and bipolar disorder, as is a monitoring plan applicable for all patients receiving antipsychotic therapy...
  15. ncbi Paliperidone: quo vadis?
    L Citrome
    Department of Psychiatry, New York University School of Medicine, and the Nathan S Kline Institute for Psychiatric Research, Orangeburg, NY 10962, USA
    Int J Clin Pract 61:653-62. 2007
    ..With the impending availability of oral risperidone as a generic medication, cost of oral paliperidone will likely become a significant obstacle to its use...
  16. ncbi Pharmacokinetics of aripiprazole and concomitant carbamazepine
    Leslie Citrome
    Nathan S Kline Institute for Psychiatric Research and Rockland Psychiatric Center, Orangeburg, NY 10962, USA
    J Clin Psychopharmacol 27:279-83. 2007
    ..Additional dose increases should be based on clinical evaluation. When carbamazepine is withdrawn from combination therapy, aripiprazole dose should then be reduced...
  17. ncbi Risk of treatment-emergent diabetes mellitus in patients receiving antipsychotics
    Leslie L Citrome
    Department of Psychiatry, School of Medicine, New York University, New York, NY, USA
    Ann Pharmacother 41:1593-603. 2007
    ..Type 2 diabetes mellitus has been reported during antipsychotic treatment...
  18. ncbi Show me the evidence: using number needed to treat
    Leslie Citrome
    Department of Psychiatry, New York University School of Medicine, USA
    South Med J 100:881-4. 2007
    ....
  19. ncbi Risperidone alone versus risperidone plus valproate in the treatment of patients with schizophrenia and hostility
    Leslie Citrome
    Nathan S Kline Institute for Psychiatric Research, Orangeburg, New York 10962, USA
    Int Clin Psychopharmacol 22:356-62. 2007
    ..In conclusion, although patients receiving combination treatment were more likely to complete the study, we were unable to detect a meaningful advantage for combination therapy as measured by rating scales...
  20. ncbi Atypical antipsychotics, elderly patients, and mortality risk
    Leslie Citrome
    New York University School of Medicine and Nathan S Kline Institute for Psychiatric Research, Orangeburg, New York 10962, USA
    South Med J 100:964-5. 2007
  21. doi Olanzapine pamoate: a stick in time? A review of the efficacy and safety profile of a new depot formulation of a second-generation antipsychotic
    L Citrome
    New York University School of Medicine, Department of Psychiatry, NY, USA
    Int J Clin Pract 63:140-50. 2009
    ..07% of injections, requiring patients to be observed for 3 h after injection. At present, there are no studies available that directly compare olanzapine pamoate with other antipsychotics other than oral olanzapine...
  22. doi Adjunctive lithium and anticonvulsants for the treatment of schizophrenia: what is the evidence?
    Leslie Citrome
    New York University School of Medicine, Department of Psychiatry, New York, USA
    Expert Rev Neurother 9:55-71. 2009
    ....
  23. doi Dose trends for second-generation antipsychotic treatment of schizophrenia and bipolar disorder
    Leslie Citrome
    Nathan S Kline Institute for Psychiatric Research, 140 Old Orangeburg Road, Orangeburg, NY 10962, USA
    Schizophr Res 108:238-44. 2009
    ..This has been reported for olanzapine and quetiapine, where higher doses are commonly used. This may be the case for ziprasidone as well...
  24. doi Asenapine for schizophrenia and bipolar disorder: a review of the efficacy and safety profile for this newly approved sublingually absorbed second-generation antipsychotic
    L Citrome
    Department of Psychiatry, New York University School of Medicine, New York, NY, USA
    Int J Clin Pract 63:1762-84. 2009
    ..To describe the efficacy and safety of asenapine for the treatment of schizophrenia and bipolar disorder...
  25. doi Impact of real-world ziprasidone dosing on treatment discontinuation rates in patients with schizophrenia or bipolar disorder
    Leslie Citrome
    Nathan S Kline Institute for Psychiatric Research, Orangeburg, NY, USA
    Schizophr Res 115:115-20. 2009
    ..The purpose of this study is to evaluate the relationship between maximum dose of ziprasidone and time to discontinuation in the treatment of schizophrenia/schizoaffective disorder and bipolar disorder in clinical practice...
  26. doi Paliperidone palmitate - review of the efficacy, safety and cost of a new second-generation depot antipsychotic medication
    L Citrome
    Department of Psychiatry, New York University School of Medicine, New York, NY, USA
    Int J Clin Pract 64:216-39. 2010
    ..To describe the efficacy, safety and cost of paliperidone palmitate, a depot antipsychotic medication recently approved for the treatment of schizophrenia...
  27. doi Iloperidone redux: a dissection of the Drug Approval Package for this newly commercialised second-generation antipsychotic
    L Citrome
    Department of Psychiatry, New York University School of Medicine and the Nathan S Kline Institute for Psychiatric Research, Orangeburg, NY, USA
    Int J Clin Pract 64:707-18. 2010
    ..To describe the contents of a Drug Approval Package and to describe the efficacy and safety of iloperidone for the treatment of schizophrenia...
  28. doi Treatment of schizophrenia with depot preparations of fluphenazine, haloperidol, and risperidone among inpatients at state-operated psychiatric facilities
    Leslie Citrome
    Nathan S Kline Institute for Psychiatric Research, 140 Old Orangeburg Road, Orangeburg, NY 10962, USA
    Schizophr Res 119:153-9. 2010
    ..This study aimed to characterize the inpatient utilization of depot antipsychotics...
  29. pmc Citability of original research and reviews in journals and their sponsored supplements
    Leslie Citrome
    Department of Psychiatry, New York University School of Medicine, New York, New York, United States of America
    PLoS ONE 5:e9876. 2010
    ..It is unknown if their contents are cited as often. The objective of this study was to quantify the citability of original research and reviews contained in supplements and compare it with that for the parent journal...
  30. doi Ziprasidone HCl capsules for the adjunctive maintenance treatment of bipolar disorder in adults
    Leslie Citrome
    Nathan S Kline Institute for Psychiatric Research, 140 Old Orangeburg Road, Orangeburg, NY 10962, USA
    Expert Rev Neurother 10:1031-7. 2010
    ..e., more robust) NNT for quetiapine in terms of proportions of subjects experiencing a mood event (NNT: 4), but a higher incidence of bodyweight gain of at least 7% from baseline...
  31. doi How to search and harvest the medical literature: let the citations come to you, and how to proceed when they do
    L Citrome
    Nathan S Kline Institute for Psychiatric Research, Orangeburg, NY 10962, USA
    Int J Clin Pract 63:1565-70. 2009
    ..There is a virtual avalanche of medical information available to clinicians and researchers. The traditional 'search' can be substantially augmented by proactive 'harvesting.'..
  32. doi Relative vs. absolute measures of benefit and risk: what's the difference?
    L Citrome
    Department of Psychiatry, New York University School of Medicine, New York and Nathan S Kline Institute for Psychiatric Research, Orangeburg, NY 10962, USA
    Acta Psychiatr Scand 121:94-102. 2010
    ..When appraising evidence clinicians are confronted with two types of comparisons: ratios, such as relative risk, and absolute differences, such as number needed to treat (NNT) or number needed to harm (NNH)...
  33. doi Iloperidone: chemistry, pharmacodynamics, pharmacokinetics and metabolism, clinical efficacy, safety and tolerability, regulatory affairs, and an opinion
    Leslie Citrome
    New York University School of Medicine, New York City, NY, USA
    Expert Opin Drug Metab Toxicol 6:1551-64. 2010
    ..Iloperidone is a newly commercialized second-generation (atypical) antipsychotic approved for the acute treatment of schizophrenia in adults...
  34. doi Effect of ziprasidone dose on all-cause discontinuation rates in acute schizophrenia and schizoaffective disorder: a post-hoc analysis of 4 fixed-dose randomized clinical trials
    Leslie Citrome
    Nathan S Kline Institute for Psychiatric Research, Orangeburg, NY 10962, USA
    Schizophr Res 111:39-45. 2009
    ..This study examines the relationship of ziprasidone dose and all-cause discontinuation in randomized clinical trials in patients with an acute exacerbation of schizophrenia or schizoaffective disorder...
  35. doi Olanzapine plasma concentrations after treatment with 10, 20, and 40 mg/d in patients with schizophrenia: an analysis of correlations with efficacy, weight gain, and prolactin concentration
    Leslie Citrome
    Clinical Research and Evaluation Facility, Nathan S Kline Institute for Psychiatric Research, Orangeburg, NY 10962, USA
    J Clin Psychopharmacol 29:278-83. 2009
    ..In conclusion, olanzapine pharmacokinetics of doses up to 40 mg/d was generally consistent with prior findings in studies with fewer subjects and/or lower doses...
  36. ncbi Quantifying risk: the role of absolute and relative measures in interpreting risk of adverse reactions from product labels of antipsychotic medications
    Leslie Citrome
    New York University School of Medicine, Department of Psychiatry, and Nathan S Kline Institute for Psychiatric Research, Orangeburg, NY 10962, USA
    Curr Drug Saf 4:229-37. 2009
    ..This supplements, but does not replace, information reported directly in clinical trial reports...
  37. doi Olanzapine dosing above the licensed range is more efficacious than lower doses: fact or fiction?
    Leslie Citrome
    Nathan S Kline Institute for Psychiatric Research, 140 Old Orangeburg Road, Orangeburg, NY 10962, USA
    Expert Rev Neurother 9:1045-58. 2009
    ..This is somewhat supported by double-blind, controlled clinical trial evidence, but only for selected patients with severe and/or persistent symptoms...
  38. doi Iloperidone for schizophrenia: a review of the efficacy and safety profile for this newly commercialised second-generation antipsychotic
    L Citrome
    New York University School of Medicine, Department of Psychiatry, and Nathan S Kline Institute for Psychiatric Research, 140 Old Orangeburg Road, Orangeburg, NY 10962, USA
    Int J Clin Pract 63:1237-48. 2009
    ..The aim of the study was to describe the efficacy and safety of iloperidone for the treatment of schizophrenia...
  39. ncbi How dosing of ziprasidone in a state hospital system differs from product labeling
    Leslie Citrome
    Nathan S Kline Institute for Psychiatric Research, Orangeburg, N Y 10962, USA
    J Clin Psychiatry 70:975-82. 2009
    ....
  40. doi Using oral ziprasidone effectively: the food effect and dose-response
    Leslie Citrome
    Department of Psychiatry, Nathan S Kline Institute for Psychiatric Research, New York University School of Medicine, Orangeburg, NY 10962, USA
    Adv Ther 26:739-48. 2009
    ..Provided that an adequate dose of ziprasidone is prescribed, and administered with a 500 kcal meal, ziprasidone can be effectively used to control symptoms without the long-term liabilities of metabolic side effects...
  41. doi Adjunctive aripiprazole, olanzapine, or quetiapine for major depressive disorder: an analysis of number needed to treat, number needed to harm, and likelihood to be helped or harmed
    Leslie Citrome
    Nathan S Kline Institute for Psychiatric Research, Orangeburg, NY 10962, USA
    Postgrad Med 122:39-48. 2010
    ..To describe the efficacy and safety of adjunctive aripiprazole, olanzapine, and quetiapine for major depressive disorder...
  42. ncbi Incidence, prevalence, and surveillance for diabetes in New York State psychiatric hospitals, 1997-2004
    Leslie Citrome
    Nathan S Kline Institute for Psychiatric Research, Orangeburg, NY 10962, USA
    Psychiatr Serv 57:1132-9. 2006
    ....
  43. ncbi The increase in risk of diabetes mellitus from exposure to second-generation antipsychotic agents
    Leslie L Citrome
    New York University School of Medicine, Department of Psychiatry, New York, NY, USA
    Drugs Today (Barc) 40:445-64. 2004
    ..Clinicians are urged to manage risk by regularly monitoring all patients receiving second-generation antipsychotic agents for the emergence of diabetes mellitus...
  44. ncbi Toward convergence in the medication treatment of bipolar disorder and schizophrenia
    Leslie Citrome
    Department of Psychiatry, New York University School of Medicine, NY, USA
    Harv Rev Psychiatry 13:28-42. 2005
    ....
  45. ncbi Use of mood stabilizers among patients with schizophrenia, 1994-2001
    Leslie Citrome
    Nathan S Kline Institute for Psychiatric Research, Orangeburg, NY 10962, USA
    Psychiatr Serv 53:1212. 2002
  46. ncbi Atypical antipsychotics for acute agitation. New intramuscular options offer advantages
    Leslie Citrome
    Nathan S Kline Institute for Psychiatric Research, 140 Old Orangeburg Rd, Orangeburg, NY 10962, USA
    Postgrad Med 112:85-8, 94-6. 2002
    ..In addition, development of depot preparations of atypical antipsychotics is progressing rapidly. These products may further revolutionize the emergency and postemergency care of psychotic patients...
  47. ncbi The many faces of bipolar disorder. How to tell them apart
    Leslie Citrome
    New York University School of Medicine, New York, USA
    Postgrad Med 117:15-6, 19-23. 2005
    ..Effective pharmacotherapy and maintenance monitoring are critical in order to minimize the risk of relapse and associated disability, morbidity, and mortality...
  48. ncbi New treatments for agitation
    Leslie Citrome
    S Kline Institute for Psychiatric Research, Orangeburg, NY 10962, USA
    Psychiatr Q 75:197-213. 2004
    ..This includes newer formulations of novel antipsychotics such as liquids and rapidly disintegrating tablets, as well as intramuscular preparations...
  49. ncbi Relationship of atypical antipsychotics with development of diabetes mellitus
    Leslie L Citrome
    New York University School of Medicine, New York, NY and Clinical Research and Evaluation Facility, Nathan S Kline Institute for Psychiatric Research, Orangeburg, NY, USA
    Ann Pharmacother 37:1849-57. 2003
    ..To review the pharmacoepidemiologic evidence for the link between exposure to atypical antipsychotics and the development of diabetes mellitus...
  50. ncbi The promise of atypical antipsychotics: fewer side effects mean enhanced compliance and improved functioning
    Leslie Citrome
    Nathan S Kline Institute for Psychiatric Research, Orangeburg, New York 10962, USA
    Postgrad Med 116:49-51, 55-9, 63. 2004
    ..In this article, the authors discuss the advantages and side effects of these agents and present a guide to help physicians choose the optimal drug in the most favorable formulation for each patient...
  51. ncbi Adjunctive divalproex and hostility among patients with schizophrenia receiving olanzapine or risperidone
    Leslie Citrome
    Nathan S Kline Institute for Psychiatric Research, 140 Old Orangeburg Road, Orangeburg, NY 10962, USA
    Psychiatr Serv 55:290-4. 2004
    ....
  52. ncbi Relationship between antipsychotic medication treatment and new cases of diabetes among psychiatric inpatients
    Leslie Citrome
    Nathan S Kline Institute for Psychiatric Research, Orangeburg, New York 10962, USA
    Psychiatr Serv 55:1006-13. 2004
    ....
  53. ncbi Schizophrenia and valproate
    Leslie Citrome
    Nathan S Kline Institute for Psychiatric Research, 140 Old Orangeburg Road, Orangeburg, NY 10962, USA
    Psychopharmacol Bull 37:74-88. 2003
    ..It is anticipated that future research will focus on the new extended-release formulation of divalproex that can be administered on a once-daily basis...
  54. ncbi Optimal dosing of atypical antipsychotics in adults: a review of the current evidence
    Leslie Citrome
    Department of Psychiatry, New York University, New York, N Y, USA
    Harv Rev Psychiatry 10:280-91. 2002
    ....
  55. ncbi Focus on the clinical ramifications of antipsychotic choice for the risk for developing type 2 diabetes mellitus
    Leslie Citrome
    New York University School of Medicine, NY, USA
    Int J Neuropsychopharmacol 8:147-51. 2005
  56. ncbi Violent patients in the emergency setting
    L Citrome
    Department of Psychiatry, New York University, New York, USA
    Psychiatr Clin North Am 22:789-801. 1999
    ..The use of typical neuroleptics may lead to side effects, such as akathisia, which may in turn precipitate additional agitation. This may be obviated with the introduction of IM preparations of atypical antipsychotics...
  57. ncbi Efficacy of ziprasidone against hostility in schizophrenia: Post hoc analysis of randomized, open-label study data
    Leslie Citrome
    Nathan S Kline Institute for Psychiatric Research and the New York University School of Medicine, Orangeburg, NY 10962, USA
    J Clin Psychiatry 67:638-42. 2006
    ..The objective was to determine the effects of sequential intramuscular/oral ziprasi-done on hostility...
  58. ncbi Changes in use of valproate and other mood stabilizers for patients with schizophrenia from 1994 to 1998
    L Citrome
    Clinical Research and Evaluation Facility, Nathan S Kline Institute for Psychiatric Research in Orangeburg, New York 10962, USA
    Psychiatr Serv 51:634-8. 2000
    ..The study describes changes over time in the adjunctive use of valproate and other mood stabilizers-lithium, carbamazepine, and gabapentin--among hospitalized psychiatric patients with a diagnosis of schizophrenia...
  59. ncbi Do guidelines for severe mental illness promote physical health and well-being?
    Leslie Citrome
    New York University School of Medicine, Department of Psychiatry, and Nathan S Kline Institute for Psychiatric Research, Orangeburg, NY, USA
    J Psychopharmacol 19:102-9. 2005
    ....
  60. ncbi A study of the safety, efficacy, and tolerability of switching from the standard delayed release preparation of divalproex sodium to the extended release formulation in patients with schizophrenia
    Leslie Citrome
    Nathan S Kline Institute for Psychiatric Research, 140 Old Orangeburg Road, Orangeburg, NY 10962, USA
    J Clin Psychopharmacol 24:255-9. 2004
    ....
  61. ncbi Metabolic syndrome and cardiovascular disease
    Leslie Citrome
    New York University School of Medicine, Department of Psychiatry, and Nathan S Kline Institute for Psychiatric Research, Orangeburg, NY, USA
    J Psychopharmacol 19:84-93. 2005
    ..Ongoing monitoring for all components of the metabolic syndrome is necessary. Individuals at high risk require multimodal interventions, including lifestyle interventions and targeted medications as appropriate...
  62. ncbi Effects of clozapine, olanzapine, risperidone, and haloperidol on hostility among patients with schizophrenia
    L Citrome
    Nathan Kline Institute for Psychiatric Research in Orangeburg, New York 10962, USA
    Psychiatr Serv 52:1510-4. 2001
    ..This study compared the specific antiaggressive effects of clozapine with those of olanzapine, risperidone, and haloperidol...
  63. ncbi Metabolic issues in patients with severe mental illness
    Leslie Citrome
    New York University School of Medicine, Department of Psychiatry, and the Nathan S Kline Institute for Psychiatric Research, Orangeburg, NY, USA
    South Med J 98:714-20. 2005
    ..Collaborative treatment between a psychiatrist and an endocrinologist is encouraged. The primary care physician may be required to fulfill both roles...
  64. ncbi Efficacy of aripiprazole against hostility in schizophrenia and schizoaffective disorder: data from 5 double-blind studies
    Jan Volavka
    The Nathan Kline Institute and New York University, 140 Old Orangeburg Road, Orangeburg, N Y 10962, USA
    J Clin Psychiatry 66:1362-6. 2005
    ..The objective was to determine the effects of aripiprazole on hostility...
  65. ncbi Neurocognitive correlates of the COMT Val(158)Met polymorphism in chronic schizophrenia
    Robert M Bilder
    Nathan S Kline Institute for Psychiatric Research, Orangeburg, NY 10962, USA
    Biol Psychiatry 52:701-7. 2002
    ....
  66. doi "Stat" medication administration predicts hospital discharge
    Ari Jaffe
    Nathan S Kline Institute for Psychiatric Research, 140 Old Orangeburg Road, Orangeburg, NY, 10962, USA
    Psychiatr Q 80:65-73. 2009
    ..This study describes the use of "stat" medications for inpatients in a large state psychiatric hospital system, and examines the relationship between receipt of a "stat" for agitation and subsequent hospital discharge...
  67. ncbi Ziprasidone for schizophrenia and bipolar disorder: a review of the clinical trials
    William M Greenberg
    Department of Psychiatry, New York University School of Medicine, New York, NY, USA
    CNS Drug Rev 13:137-77. 2007
    ....
  68. ncbi Latest therapies for bipolar disorder. Looking beyond lithium
    Joseph F Goldberg
    Department of Psychiatry Research, Zucker Hillside Hospital, North Shore Long Island Jewish Health System, Glen Oaks, New York, USA
    Postgrad Med 117:25-6, 29-32, 35-6. 2005
    ..Maintenance treatments that have received FDA approval include olanzapine and lamotrigine. Off-label use of adjunctive medications may be required to target residual symptoms...
  69. doi Heterogeneity of violence in schizophrenia and implications for long-term treatment
    J Volavka
    Department of Psychiatry, New York University School of Medicine, New York, NY, USA
    Int J Clin Pract 62:1237-45. 2008
    ..The aim of this review is to address the subtyping of violent behaviour in schizophrenia, and to relate the subtypes to treatment...
  70. ncbi Pharmacokinetics of aripiprazole and concomitant lithium and valproate
    Leslie Citrome
    Nathan S Kline Institute for Psychiatic Research and the Rockland Psychiatric Center, Orangeburg, NY 10962, USA
    J Clin Pharmacol 45:89-93. 2005
    ..Therapeutic doses of lithium and divalproex had no clinically significant effects on the pharmacokinetics of aripiprazole in patients with schizophrenia or schizoaffective disorder...
  71. ncbi Olanzapine for schizophrenia refractory to typical and atypical antipsychotics: an open-label, prospective trial
    J P Lindenmayer
    Psychopharmacology Research Unit, Manhattan Psychiatric Unit, Manhattan Psychiatric Center, Wards Island, New York 10035, USA
    J Clin Psychopharmacol 21:448-53. 2001
    ..However, a trial with olanzapine can be recommended in these patients before moving to augmentation strategies, given the lack of proven alternatives and the observation that 16.7% of patients reached the response criteria...
  72. ncbi New antipsychotic medications: what advantages do they offer?
    L Citrome
    New York University, Orangeburg, USA
    Postgrad Med 101:207-10, 213-4. 1997
    ..Safety, efficacy, and cost will guide their use. None of these newer agents have been compared head-to-head with clozapine. More research is needed to place these new drugs into clinical perspective...
  73. ncbi Atypical antipsychotics in the treatment of the persistently aggressive psychotic patient: methodological concerns
    J Volavka
    New York University, Department of Psychiatry, Nathan Kline Institue for Psychiatric Research, Orangeburg 10962, USA
    Schizophr Res 35:S23-33. 1999
    ..g. randomization) used in typical designs of psychopharmacological clinical trials. Current research methods should be modified and new ones developed in order to progress in assessing the antiaggressive effects of treatments...
  74. ncbi The psychopharmacology of violence with emphasis on schizophrenia, part 1: acute treatment
    Leslie Citrome
    Department of Psychiatry, New York University School of Medicine, New York, NY, USA
    J Clin Psychiatry 68:163-4. 2007
  75. ncbi Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder
    Robert M Bilder
    Nathan S Kline Institute for Psychiatric Research, Orangeburg, NY 10962, USA
    Am J Psychiatry 159:1018-28. 2002
    ....
  76. ncbi Antipsychotic-induced weight gain and therapeutic response: a differential association
    Pal Czobor
    Nathan S Kline Institute for Psychiatric Research, Orangeburg, New York 10962, USA
    J Clin Psychopharmacol 22:244-51. 2002
    ..These findings suggest that patients who are likely to have the maximal benefits of olanzapine or clozapine treatment for symptom alleviation are at the highest risk of a clinically significant increase in weight gain...
  77. doi Spirituality, schizophrenia, and state hospitals: program description and characteristics of self-selected attendees of a spirituality therapeutic group
    Nadine Revheim
    Nathan S Kline Institute for Psychiatric Research, 140 Old Orangeburg Road, Orangeburg, NY 10962, USA
    Psychiatr Q 81:285-92. 2010
    ..These findings lend support for offering spirituality groups and positive coping during recovery from psychiatric disabilities...
  78. ncbi Reducing inpatient aggression: does paying attention pay off?
    Karen A Nolan
    Nathan S Kline Institute for Psychiatric Research, 140 Old Orangeburg Road, Orangeburg, NY 10962, USA
    Psychiatr Q 79:91-5. 2008
    ..Video technology can improve detection, but is labor-intensive and costly. We examined the effectiveness of interventions to improve reporting on a secure inpatient research unit equipped with audio/video surveillance...
  79. ncbi Commentary: bipolar disorder is a potentially fatal disease
    Leslie Citrome
    New York State University School of Medicine, New York
    Postgrad Med 117:9-11. 2005
  80. ncbi Effects of atypical antipsychotics on the syndromal profile in treatment-resistant schizophrenia
    Jean Pierre Lindenmayer
    Nathan Kline Institute, Orangeburg, N Y, USA
    J Clin Psychiatry 65:551-6. 2004
    ..We are exploring whether this expanded clinical efficacy can also be seen in patients with treatment-resistant schizophrenia...
  81. ncbi Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics
    Jean Pierre Lindenmayer
    Nathan Kline Institute fo Psychiatric Research, New York, NY 10035, USA
    Am J Psychiatry 160:290-6. 2003
    ....
  82. ncbi Prolactin levels in schizophrenia and schizoaffective disorder patients treated with clozapine, olanzapine, risperidone, or haloperidol
    Jan Volavka
    Nathan Kline Institute, Orangeburg, NY 10982, USA
    J Clin Psychiatry 65:57-61. 2004
    ....
  83. ncbi Efficacy of the branched-chain amino acids in the treatment of tardive dyskinesia in men
    Mary Ann Richardson
    Division of Movement Disorders and Molecular Psychiatry, Nathan S Kine Institute for Psychiatric Research, Orangeburg, NY 10962, USA
    Am J Psychiatry 160:1117-24. 2003
    ..The efficacy of the branched-chain amino acids in the treatment of tardive dyskinesia in men with psychiatric disorders was tested...
  84. doi Loss aversion in schizophrenia
    Fabien Tremeau
    Nathan S Kline Institute for Psychiatric Research, Orangeburg, New York 10962, United States
    Schizophr Res 103:121-8. 2008
    ..Loss aversion is conceived as an affective interference in cognitive processes such as judgment and decision-making. Loss aversion in non-risky choices has not been studied in schizophrenia...
  85. ncbi Update on the biological treatment of aggression
    J Volavka
    Nathan S Kline Institute for Psychiatric Research, New York University, USA
    Actas Esp Psiquiatr 34:123-35. 2006
    ..The heterogeneity of aggressive behavior is a challenge for developing rational treatments. Emerging genetic findings hold a promise of future treatments of aggressive behavior developed on the basis of individual patients' genotypes...
  86. ncbi Aggression and psychopathology in treatment-resistant inpatients with schizophrenia and schizoaffective disorder
    Karen A Nolan
    Nathan Kline Institute for Psychiatric Research, 140 Old Orangeburg Road, Orangeburg, NY 10962, USA
    J Psychiatr Res 39:109-15. 2005
    ..These findings in chronic, treatment resistant inpatients support the view that positive symptoms may lead to aggression...
  87. pmc Aggression and quantitative MRI measures of caudate in patients with chronic schizophrenia or schizoaffective disorder
    Matthew J Hoptman
    Nathan S Kline Institute for Psychiatric Research, Orangeburg, NY 10962, USA
    J Neuropsychiatry Clin Neurosci 18:509-15. 2006
    ..The relationship between aggression and caudate volumes may be related to the iatrogenic effects of long-term treatment with typical antipsychotic agents or to a direct effect of schizophrenic processes on the caudate...
  88. ncbi Intramuscular aripiprazole in the control of agitation
    Glenn W Currier
    Department of Psychiatry, University of Rochester Medical Center, Rochester, NY 14642, USA
    J Psychiatr Pract 13:159-69. 2007
    ..To evaluate response to intramuscular (IM) aripiprazole injections using secondary analyses from clinical trials...
  89. pmc Quantitative MRI measures of orbitofrontal cortex in patients with chronic schizophrenia or schizoaffective disorder
    Matthew J Hoptman
    Nathan S Kline Institute for Psychiatric Research, Orangeburg, NY 10962, USA
    Psychiatry Res 140:133-45. 2005
    ..Larger left OFC gray matter volumes and larger OFC white matter volumes bilaterally were associated with greater levels of aggression. These findings are discussed in the context of potential iatrogenic effects...
  90. ncbi Characteristics of assaultive behavior among psychiatric inpatients
    Karen A Nolan
    Nathan S Kline Institute for Psychiatric Research, 140 Old Orangeburg Road, Orangeburg, New York 10962, USA
    Psychiatr Serv 54:1012-6. 2003
    ..The purpose of this study was to assess the extent to which psychosis, disordered impulse control, and psychopathy contribute to assaults among psychiatric inpatients...
  91. ncbi Antipsychotic medication and diabetes mellitus
    Leslie L Citrome
    J Clin Psychiatry 66:395; author reply 395. 2005
  92. pmc Efficacy should drive atypical antipsychotic treatment
    Leslie L Citrome
    BMJ 326:283. 2003
  93. ncbi Catechol-O-methyltransferase and monoamine oxidase-A polymorphisms and treatment response to typical and atypical neuroleptics
    Karen A Nolan
    J Clin Psychopharmacol 26:338-40. 2006